Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Current Assets: 2010-2025

Historic Current Assets for Myriad Genetics (MYGN) over the last 15 years, with Sep 2025 value amounting to $344.8 million.

  • Myriad Genetics' Current Assets rose 17.60% to $344.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $344.8 million, marking a year-over-year increase of 17.60%. This contributed to the annual value of $298.0 million for FY2024, which is 4.97% down from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Current Assets is $344.8 million, which was up 21.28% from $284.3 million recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Current Assets peaked at $538.9 million during Q2 2021, and registered a low of $261.6 million during Q1 2023.
  • For the 3-year period, Myriad Genetics' Current Assets averaged around $293.1 million, with its median value being $291.6 million (2024).
  • As far as peak fluctuations go, Myriad Genetics' Current Assets surged by 62.47% in 2021, and later crashed by 43.36% in 2022.
  • Quarterly analysis of 5 years shows Myriad Genetics' Current Assets stood at $484.8 million in 2021, then slumped by 43.36% to $274.6 million in 2022, then increased by 14.20% to $313.6 million in 2023, then declined by 4.97% to $298.0 million in 2024, then rose by 17.60% to $344.8 million in 2025.
  • Its last three reported values are $344.8 million in Q3 2025, $284.3 million for Q2 2025, and $287.2 million during Q1 2025.